Effectiveness of a fenofibrate 145-mg nanoparticle tablet formulation compared with the standard 160-mg tablet in patients with coronary heart disease and dyslipidemia

Pharmacotherapy

Volumn 28, Issue 5 PART 1, 2008, Pages 570-575

  Maciejewski, Stephanie ^a   Hilleman, Daniel ^a  

^a CREIGHTON UNIVERSITY CARDIAC CENTER   (United States)

Author keywords

Coronary heart disease; Dyslipidemia; Fenofibrate; Nanoparticle formulation

Indexed keywords

FENOFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NANOPARTICLE; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG SUBSTITUTION; DYSLIPIDEMIA; EDUCATION PROGRAM; FEMALE; HEALTH PROGRAM; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OUTPATIENT DEPARTMENT; RETROSPECTIVE STUDY; TABLET FORMULATION; TRIACYLGLYCEROL BLOOD LEVEL; UNITED STATES;

ADULT; AGED; ANTILIPEMIC AGENTS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY DISEASE; DYSLIPIDEMIAS; FEMALE; HUMANS; MALE; MIDDLE AGED; NANOPARTICLES; PROCETOFEN; TABLETS; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 42949097639     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.28.5.570     Document Type: Article

References (19)

1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001;285:2486-97.
2. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program adult treatment panel III guidelines. Circulation 2004;110:227-39.
3. Castelli WP. Epidemiology of triglycerides: a view from Framingham. Am J Cardiol 1992;70:H3-9.
4. Abdel-Maksoud MF, Hokanson JE. The complex role of triglycerides in cardiovascular disease. Semin Vasc Med 2002;2:325-33.
5. Sueta CA, Chowdhury M, Boccuzzi SJ, et al. Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease. Am J Cardiol 1999;83:1303-7.
6. Hoskins MH, Jacobson TA. Missed opportunity in the treatment of hyperlipidemia in patients with coronary heart disease: the primary care setting. J Natl Med Assoc 2006;98:58-62.
7. Alsheikh-Ali AA, Lin J, Abourjaily P, Ahearn D, Kuvin JT, Karas RH. Extent to which accepted serum lipid goals are achieved in a contemporary general medical population with coronary heart disease risk equivalents. Am J Cardiol 2006;98:1231-3.
8. Yan AT, Yan RT, Tan M, et al. Contemporary management of dyslipidemia in high-risk patients: targets still not met. Am J Med 2006;119:676-83.
9. Stacy TA, Egger A. Results of retrospective chart review to determine improvement in lipid goal attainment in patients treated by high-volume prescribers of lipid-modifying drugs. J Manag Care Pharm 2006;12:745-51.
10. Keevil JG, Cullen MW, Gangnon R, McBride PE, Stein JH. Implications of cardiac risk and low-density lipoprotein cholesterol distributions in the United States for the diagnosis and treatment of dyslipidemia: data from the national health and nutrition examination survey 1999 to 2002. Circulation 2007;115:1363-70.
11. Mosca L, Linfante AH, Benjamine EJ, et al. National study of physician awareness and adherence to cardiovascular disease prevention guidelines. Circulation 2005;111:499-510.
12. Whitley HP, Fermo JD, Chumney ECG. A 5-year evaluation of electronic medical record flag alerts for patients warranting secondary prevention of coronary heart disease. Pharmacotherapy 2006;26:682-8.
13. Abbott Laboratories. Tricor (fenofibrate) package insert. Abbott Park, IL; 2004.
14. Center for Drug Evaluation and Research. 2004a. Fenofibrate: pharmacology review. Available from http://www.fda.gov/cder/foi/nda/2004/ 021656s000_Tricor_PharmR.pdf. Accessed May 31, 2006.
15. Center for Drug Evaluation and Research. 2004b. Fenofibrate: clinical pharmacology and biopharmaceutics review(s). Available from http://www.fda.gov/cder/foi/nda/2004/021656s000_Tricor_BioPharmR.pdf. Accessed May 31, 2006.
16. Sauron R, Wilkins M, Jessent V, Dubois A, Maillot C, Weil A. Absence of a food effect with a 145-mg nanoparticle fenofibrate tablet formulation. Int J Clin Pharmacol Ther 2006;44:64-70.
17. Anonymous. Tricor. Physicians' desk reference, 60th ed. Montvale, NJ: Thomson PDR, 2006:523-6.
18. Pan WJ, Gustavson LE, Achari R, et al. Lack of a clinically significant pharmacokinetic interaction between fenofibrate and pravastatin in healthy volunteers. J Clin Pharmacol 2000;40:316-23.
19. Davidson MH, Armani A, McKenney JM, Jacobson TA. Safety considerations with fibrate therapy. Am J Cardiol 2007;99(6 suppl 1):S3-18.